Active Pharmaceutical Ingredients Market, by API Type (Chemical API,Biological API), by Drug Type (Prescription,Over-the-counter (OTC) Drugs), by by Therapy Area (Cardiovascular Drugs,Oncology Drugs,Neurology Drugs,Endocrinology Drugs,Gastroenterology Drugs,Infectious Diseases Drugs,Respiratory Drugs,Others), by End User (Pharma and Biotechnology Companies,Contract Research Organization,Contract Manufacturing Organization) and Region: Global Opportunity Analysis and Industry Forecast, 2023-2033

Increase in Abbreviated New Drug Applications (ANDA) over the past years has fostered the demand for API market. Furthermore, Indian companies making increased entries related to Drug Master File (DMF) indicates APIs market gaining traction. Stringent regulatory policies in the European Union is likely to restrain market growth. Patent expiry of biological drugs creates new growth opportunities for key API manufacturers.

The report segments the market on the basis of synthesis, type of manufacturer, type and therapy. Based on synthesis, this market is segmented into synthetic API and biotech API. The former is further segmented into Innovative synthetic APIS and generic synthetic APIS, while the latter is further segmented on the basis of products and type. The biotech APIS market, by product is further segmented into monoclonal antibodies, recombinant proteins and vaccines. On the basis of type of manufacturer, this market is segmented into captive API manufacturers, merchant API manufacturers, innovative APIS and generic APIS. On the basis of type, the market is segmented into innovative APIS segment and generic APIS segment. On the basis of therapy, the market is segmented into oncology, diabetes, cardiovascular disease, Cns and neurological disorders, orthopedic disorders, nephrology, ophthalmology, pulmonology, gastrointestinal disorders and endocrinology.

On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, and Latin America, Middle East & Africa (LAMEA).

Key market players in this market are Teva Pharmaceutical Industries Limited, Dr. Reddys Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Novartis International AG, Albemarle Corporation, Sigma-Aldrich Corporation, Mylan Inc., and Allergan PLC

KEY BENEFITS FOR STAKEHOLDERS:

• The report provides a comprehensive analysis of current & future market trends, key market challenges and emerging avenues for the growth of this market globally.
• The report offers latest technological innovations and the recent R&D developments.
• The report offers an insight into competitive landscape in terms of new technological developments, untapped segments, and value chain analysis.
• This report entails the detailed quantitative analysis of the current market and estimations which assists in identifying the prevailing market opportunities.
• The report offers detailed segmentation and analyzes the key segments in terms of market size by value and volume and country-level analysis to provide an in-depth understanding of the market.
• Porters Five Forces analysis is offered in the report along with highlighting bargaining power of buyers and suppliers.
• The report offers strategic analysis of financial status of key market players, and highlights market share of key vendors.
• The report offers information on the status of new projects along with offering investment feasibility analysis of the same.

  Active Pharmaceutical Ingredients Market, by API Type Report Highlights

Aspects	Details
By API Type	Chemical API Biological API
By Drug Type	Prescription Over-the-counter (OTC) Drugs
By Therapy Area	Cardiovascular Drugs Amlodipine Atenolol Metoprolol Succinate Furosemide Oncology Drugs Fluconazole Ketoconazole Montelukast Sodium Sumatriptan Succinate Neurology Drugs Gabapentin Levocetirizine dihydrochloride Venlafaxine HCL Donepezil Endocrinology Drugs Glimepiride Metformin HCL Levothyroxine Pioglitazone Gastroenterology Drugs Bisacodyl Omeprazole Pantaprazole Loperamide Infectious Diseases Drugs Nitrofurantoin Sulfadoxine Pyrimethamine Ciprofloxacin HCL Respiratory Drugs Ambroxol HCl Bromhexine HCl Terbutaline Sulphate Salbutamol Sulphate Others Sulfadoxine Albendazole Chlorhexidine Gluconate Mebendazole
By End User	Pharma and Biotechnology Companies Contract Research Organization Contract Manufacturing Organization
By Region	North America  (U.S., Canada, MEXICO) Europe  (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players	Sandoz, Dr. Reddy’s Laboratories Ltd., Eli Lilly And Company., Pfizer Inc., Aurobindo Pharma, Merck KGaA, Cipla, AbbVie Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals

^*Terms and Conditions Apply